Company Overview of Mylan Laboratories Limited
Mylan Laboratories Limited manufactures and supplies active pharmaceutical ingredients in India. It also manufactures finished dosage formulations and injectables; and engages in research and development activities. The company was formerly known as Matrix Laboratories Limited and changed its name to Mylan Laboratories Limited in October 2011. Mylan Laboratories Limited was founded in 2001 and is based in Hyderabad, India. Mylan Laboratories Limited is a subsidiary of Mylan N.V.
Plot No. 564/A/22
Road No. 92
Founded in 2001
Key Executives for Mylan Laboratories Limited
Chief Executive Officer and Managing Director
Chief Financial Officer and Executive Director
Executive VP of Strategic Business Planning & Emerging Business and Member of Advisory Board
Executive Vice President of Supply Chain & Management Services and Member of Advisory Board
Compensation as of Fiscal Year 2017.
Mylan Laboratories Limited Key Developments
Horizon Pharma plc Announces District Court Decision to Uphold VIMOVO® (Naproxen/Esomeprazole Magnesium) Patents
Jun 27 17
Horizon Pharma plc announced that the United States District Court for the District of New Jersey upheld the validity of two Horizon Pharma patents covering VIMOVO® (naproxen/esomeprazole magnesium), and that Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd., Mylan Pharmaceuticals Inc., Mylan Laboratories Ltd., and Mylan Inc., and Lupin Ltd. and Lupin Pharmaceuticals Inc. would infringe at least one of the two patents with their proposed generic naproxen/esomeprazole magnesium products. On April 21, 2011, July 25, 2011, and June 28, 2013, Horizon filed patent infringement lawsuits in District Court against Dr. Reddy’s, Lupin, and Mylan, respectively, related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration to market generic versions of VIMOVO. The lawsuits claim infringement of Horizon's U.S. Patent Nos. 8,557,285 (‘285 patent) and 6,926,907 (‘907 patent) titled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs,” which cover VIMOVO. The District Court’s decision was made based on the validity of Horizon Pharma’s ‘285 and ‘907 patents for VIMOVO and the Court’s judgment will prevent Dr. Reddy’s, Mylan, and Lupin from launching generic versions of VIMOVO in the United States.
Mylan Laboratories Limited Reports Unaudited Standalone Earnings Results for the Six Months and Year Ended March 31, 2016
May 13 16
Mylan Laboratories Limited reported unaudited standalone earnings results for the six months and year ended March 31, 2016. For the six months, net sales/income from operation was INR 43,196.8 million against INR 40,037.8 million a year ago. Loss from operation before other income, interest and exceptional items was INR 454.5 million against profit from operation before other income, interest and exceptional items of INR 758.5 million a year ago. Profit before interest and exceptional items were INR 1,384.9 million against INR 3,069.0 million a year ago. Net loss was INR 1,729.1 million or INR 7.59 per basic and diluted share against net profit of INR 214.2 million or INR 1.13 per basic and diluted share a year ago.
For the year, net sales/income from operation was INR 92,047.4 million against INR 78,044.1 million a year ago. Profit from operation before other income, interest and exceptional items were INR 2,822.4 million against INR 1,406.4 million a year ago. Profit before interest and exceptional items were INR 6,220.6 million against INR 6,359.8 million a year ago. Net profit was INR 86.2 million or INR 0.41 per basic and diluted share against INR 1,342.8 million or INR 7.09 per basic and diluted share a year ago.
Mylan Laboratories Limited, Board Meeting, May 12, 2016
May 13 16
Mylan Laboratories Limited, Board Meeting, May 12, 2016. Agenda: To consider unaudited earnings results for the six months and year ended March 31, 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|